Chronic Pain and Substance Use in Patients with Hepatitis C

描述（由申请人提供）：这个指导以患者为导向的研究职业发展奖（K23）的目标是本杰明Morasco，博士。成为一名独立的科学家，研究用于评估和治疗丙型肝炎患者慢性疼痛和共病物质使用障碍（SLID）的创新方法。候选人提出了一个研究和培训计划，目标如下：进一步了解疼痛，成瘾和SLID;扩大他对疼痛和SLID非药物治疗策略的了解;发展丙型肝炎病毒（HCV）患者心理社会需求的专业知识;并获得先进的研究技能，为他作为独立研究者的职业生涯做好准备。Morasco博士将与他的导师Peter Mauser博士，Dennis Turk博士，Alan Marlatt博士和Steven Dobscha博士密切合作，以实现上述目标。俄勒冈州健康与科学大学和波特兰VA医疗中心的资源，加上指导团队的专家指导，将为Morasco博士提供理想的机会，以发展评估和治疗共病疼痛和SLID的专业知识。作为K23奖项的一部分，Morasco博士将（1）进行一项横断面研究，检查与HCV患者慢性疼痛相关的生物心理社会因素，（2）开发和试点测试基于群体的认知行为治疗，以减轻疼痛，改善身体和情绪功能，并减少HCV患者的物质使用。这些研究的结果将用于申请R 01基金，以在随机对照试验中测试新开发的干预措施。本研究的长期目标是更好地了解HCV患者的治疗需求，并最终改善该患者人群中疼痛和共病物质使用的治疗。成功完成拟议的研究将使Morasco博士成为一名独立的研究者，在疼痛和SLID的联合治疗方面具有专业知识，特别是在HCV患者中进行临床研究。与公共卫生的相关性：我们希望这个项目将有助于丙型肝炎患者疼痛因素的必要信息。如果新开发的治疗方法有效，丙型肝炎患者的健康相关生活质量将得到改善。

DESCRIPTION (provided by applicant): The goal of this Mentored Patient-Oriented Research Career Development Award (K23) is for Benjamin Morasco, Ph.D. to become an independent scientist studying innovative approaches for the assessment and treatment of chronic pain and comorbid substance use disorder (SLID) in patients with hepatitis C. The candidate proposes a program of research and training with the following goals: further his understanding of pain, addiction, and SLID; expand his knowledge regarding strategies to address the non-pharmacological treatment of pain and SLID; develop expertise in the psychosocial needs of patients with the hepatitis C virus (HCV); and acquire advanced research skills that will prepare him for a career as an independent investigator. Dr. Morasco will work closely with his mentors, Drs. Peter Mauser, Dennis Turk, Alan Marlatt, and Steven Dobscha throughout the course of this award to meet the above objectives. The resources at the Oregon Health & Science University and Portland VA Medical Center, combined with the expert guidance of the mentoring team, will provide the ideal opportunity for Dr. Morasco to develop expertise in the assessment and treatment of comorbid pain and SLID. As part of this K23 award, Dr. Morasco will (1) conduct a cross-sectional study examining the biopsychosocial factors that are associated with chronic pain in patients with HCV, and (2) develop and pilot test a group-based cognitive-behavioral treatment to reduce pain, improve physical and emotional functioning, and reduce substance use in patients with HCV. Results from these studies will be used to apply for R01 funding to test the newly developed intervention in a randomized controlled trial. The long-term goal of this research is to develop a better understanding of the treatment needs of HCV patients, and ultimately improve the treatment of pain and comorbid substance use in this patient population. Successful completion of the proposed studies will prepare Dr. Morasco to become an independent investigator with expertise conducting clinical research in the combined treatment of pain and SLID, particularly in patients with HCV. Relevance to Public Health: We expect that this project will contribute needed information about the factors that contribute to pain in patients with hepatitis C. If the newly developed treatment is effective, the health-related quality of life among hepatitis C patients will be improved.